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ttp://dx.doi.org/10.1016/j.ajpath.2014.02.022Neonatal hypoxic-ischemic encephalopathy (HIE) remains a serious burden in neonatal care. Hypo-
thermia provides a good outcome in some babies with HIE. Here, we investigated the biological
mechanisms of its neuroprotective effect and sought for a new therapeutic target. We made neonatal
HIE rats and subjected some of them to hypothermia at 28C for 3 hours. We pathologically conﬁrmed
the efﬁcacy of hypothermia against the neonatal HIE brain. To clarify the molecular mechanism of
hypothermia’s efﬁcacy, we analyzed mRNA expression, immunoassay, and pathology in the brain with or
without HIE and/or hypothermia. We selected from these analyses 12 molecules with possible neuro-
protective effects. After identiﬁcation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)
as a therapeutic target candidate, we examined the efﬁcacy of an antieLOX-1 neutralizing antibody in
neonatal HIE rats. Administration of an antieLOX-1 neutralizing antibody reduced infarction area, brain
edema, and apoptotic cell death to a degree comparable with hypothermia. Protection from those
pathological conditions was considered part of the therapeutic mechanism of hypothermia. The efﬁcacy
of administering antieLOX-1 neutralizing antibody was similar to that of hypothermia. LOX-1 is a
promising therapeutic target in neonatal HIE, and the inhibition of LOX-1 may become a novel
treatment for babies who have experienced asphyxia. (Am J Pathol 2014, 184: 1843e1852; http://
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Disclosures: None declared.Neonatal hypoxic-ischemic encephalopathy (HIE) is a main
cause of perinatal brain damage. The mortality ranges from
10% to 60%, and 25% of survivors have neurological
sequel, such as cerebral palsy, mental retardation, deafness,
and epilepsy.1,2 Prevention and treatment of neonatal HIE
remains to be established until now. Neonatal HIE occurs
after asphyxia and is induced by the combination of intrinsic
and environmental factors.3,4 Although many animal ex-
periments and clinical trials have been performed, much
remains unsolved as to the pathophysiology, biology, and
therapy of neonatal HIE.
Despite the remarkable progress in neonatal care for the
past two decades, neonatal HIE has not shown a signiﬁcant
decline with an incidence of 1 to 6 per 1000 live births.5
Novel pharmacological treatments, such as erythropoietin
and xenon, have been attempted with babies who have
experienced asphyxia, but they have not led to a substantial
improvement.6 Since the 1990s, hypothermia (HT) has been
applied to babies who have experienced asphyxia as a newstigative Pathology.
.therapy. Three large-scale randomized controlled studies of
HT for term infants with HIE reported that head or whole-
body cooling signiﬁcantly reduces neurological sequel.7e9
HT exerts a neuroprotective effect by reducing energy con-
sumption and by repressing glutamate release and free radi-
cals.10 Experimental HT for neonatal HIE involves many
cytoplasmic cascades or pathways such as the excito-
oxidative cascade that involves lactic acid, glutamate, nitric
oxide, mitochondrial failure, free radicals, lipid peroxidation,
and inﬂammation.11e14 We previously demonstrated that
Akamatsu et aledaravon, an antioxidative agent, is effective in a rat model of
neonatal HIE with a signiﬁcant reduction in neuronal
apoptosis and infarct areas.15 These biological pathways
obviously conclude in apoptotic cell death.
By contrast, HT after brain injury is useful for controlling
intracranial pressure caused by brain edema.16 However, in
the rewarming period, a rebound rise is often seen in intra-
cranial pressure because of leakage from the blood-brain
barrier (BBB), resulting in brain damage.16 In the devel-
oping brain, the BBB is vulnerable to various stresses.17
Protection against a BBB break is needed during the care
of an immature brain. Taken together, it is important to rescue
the asphyxiated baby brain by inhibiting the progress of brain
edema and the activation of apoptotic cell death. Much re-
mains to be elucidated as to the biological and molecular
mechanisms of the neuroprotective effect of HT.
In the present study, we explored the molecular mecha-
nism of the neuroprotective effect of HT against neonatal
HIE and identiﬁed lectin-like oxidized low-density lipo-
protein receptor-1 (LOX-1) as a new therapeutic target.
Furthermore, we evaluated the effect of a new treatment by
blocking LOX-1 in the asphyxiated neonatal brain.
Materials and Methods
All experiments were conducted according to the protocols
approved by the Animal Experiment Ethical Committee of
the National Center of Neurology and Psychiatry. Animals
were housed under a 12-hour:12-hour light/dark cycle with
food and water available ad libitum.
Animal Preparation and Neonatal HIE Model
We used Sprague-Dawley rat pups (CLEA Japan Inc.,
Tokyo, Japan) on postnatal day 7 in all experiments. In the
initial experiments, pups were assigned to three groups:
control (CTL), neonatal HIE, and HT. In addition, an
experiment was conducted on other groups of pups for a
therapeutic trial. The sample distribution is summarized in
Supplemental Table S1. CTL pups were kept at 36C for 3
hours and underwent neither surgical procedure nor hypoxic
exposure. HIE pups received left common carotid artery
ligation and were kept under 8% O2 at 36C for 2 hours
[hypoxic-ischemic (HI) insult], according to Rice’s
method,18 and then at 36C for the next 3 hours, resulting in
lesion in the left hemisphere. At ﬁrst, to decide a suitable
temperature for HT treatment, we experimented with HT
pups at 28C or 32C after HI insult and performed mRNA
expression assays (Supplemental Table S2). We conﬁrmed
that the number of 28C HT-induced genes was similar to
that of 32C HT-induced genes (Supplemental Table S3).
Moreover, the brain infarction area of 28C HT pups was
smaller than that of 32C HT pups (data not shown). The
28C HT experiment was adapted as HT in the study. HT
pups were kept on HT of 28C for 3 hours immediately after
HI insult. Therapeutic trial pups were administered an agent1844immediately after HI insult. In each experiment, a
temperature-monitored pup was kept at 36C or 28C by a
controller (ACT-101B; Unique Medical, Tokyo, Japan).19,20
After these procedures, all pups were kept with their mothers
as usual (12-hour:12-hour light/dark cycle) until sacriﬁce.
Tissue Preparation and Pathological Analyses
Pup brains were removed at 3, 6, 24, 48, or 72 hours after
the procedures of control, HI insult, HT, and therapeutic
trial. After being anesthetized, they were perfused intracar-
dially with PBS or 4% paraformaldehyde in PBS. For
expression analyses, perfusion was done with PBS, and then
the brains were stored at 80C until use.
For histopathological analyses, the brains were perfused
with paraformaldehyde, removed, additionally inﬁltrated
with paraformaldehyde at 4C for 24 hours, embedded in
parafﬁn, and cut into coronal serial sections (4 mm thick). The
sections were then subjected to various staining, such as Nissl
staining, TUNEL assay, and in situ hybridization. To eval-
uate apoptotic cell death, TUNEL assay was performed with
ApopTag Fluorescein In Situ Apoptosis Detection Kit (Mil-
lipore, Billerica, MA) and antifade solution that contained
DAPI. We counted all TUNELþ cells and/or DAPIþ cells in
four 1-mm2 ﬁelds in the left cortex at 400 magniﬁcation.
We calculated the ratio (apoptotic ratio) of the TUNEL and
DAPI doubleþ cell number to the DAPIþ cell number and
calculated the mean and SD from four ﬁelds in each animal.
In addition, TUNEL sections were double-stained with anti-
NeuN mouse antibody (Millipore) to identify neurons.
Moreover, we performed immunohistochemistry to
conﬁrm LOX-1 expression in brains. Coronal sections of
frozen rat brains (10 mm thick) were stained with a chicken
polyclonal LOX-1 antibody (provided by Dr. T. Sawamura)
and a secondary antibody of Alex Fluor 488-conjugated
donkey anti-chicken IgY (Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA).21 All ﬂuorescence sections
were observed with a ﬂuorescent microscope (BX51;
Olympus, Tokyo, Japan).
Evaluation of Brain Edema and Infarction
For brain edema evaluation, we measured the brain-water
content. Fresh unﬁxed brains 24, 48, and 72 hours after HI
insult were divided into the left and right hemispheres. Each
hemisphere was weighed immediately after removal (wet
weight), and, after drying in an oven at 85C for 72 hours,the
same hemisphere was weighed again (dry weight). The ratio of
½ðwet weightÞ  ðdry weightÞ=ðwet weightÞ was calculated
as the water content ratio. The ratio of the lesional side water
content ratio to the nonlesional side water content ratio was
deﬁned as an edema ratio and was used to compare the groups.
We evaluated the infarct size at the hippocampus and
hypothalamus levels with Nissl staining. Nissl-stained sec-
tions were photographed at 20 magniﬁcation with a mi-
croscope (BX51; Olympus), and ImageJ software, versionajp.amjpathol.org - The American Journal of Pathology
LOX-1 Is Neonatal HIE Therapeutic Target1.45 (NIH, Bethesda,MD) was used to measure the intact and
whole area in both the lesional and nonlesional sides. Then
we calculated the ratio of the lesional side intact area to the
nonlesional side intact area as the ratio of the intact area.
Exploration of Molecules Accounting for the
Effects of HT
We made protein extracts and mRNA extracts from the stored
samples. For whole mRNA expression analysis, we performed
microarray analysis of CTL, HIE, and HT brains, using Gen-
eChip Rat Gene 1.0 ST Array (Affymetrix, Santa Clara, CA)
according to the manufacturer’s instructions. In the compari-
son of mRNA expression data between CTL and HIE brains,
we selected genes of HIE/CTL> 3 as up-regulation, and HIE/
CTL < 0.5 as down-regulation. To conﬁrm the expression
levels of the genes found in this study, we performed real-time
quantitative PCR (qPCR) and in situ hybridization of more
than four brains from each group and age, using TaqMan gene
expression assays and master mix (Applied Biosystems,
Carlsbad, CA) with Lightcycler 480 II (Roche, Basel,
Switzerland). A standard reference gene of glyceraldehyde-
3ephosphate dehydrogenase (GAPDH ) was used as a
normalization reference. Furthermore, we performed in situ
hybridization analysis, using PCR DIG Probe Synthesis KitFigure 1 Differences among brains of the CTL (A), HIE (48 hours after HI insu
coronal sections with Nissl staining denotes infarction. D: The ratios of intact area
signiﬁcantly higher in HT than in HIE (24 to 72 hours). Data are expressed as m
The American Journal of Pathology - ajp.amjpathol.org(Roche). The probes’ primer sequences were as follows: the
forward primer of P2ry13 (purinergic receptor P2Y, G-protein
coupled 13), 50-CCTGGGGCTGCTGTGGCATC-30; the
reverse primer of P2ry13, 50-TTCGCCTCCAGCCGCTT-
GTG-30; the forward primer of Olr1 (oxidized low-density
lipoprotein receptor 1), 50-TGACCCTGCCATGCCATG-
CT-30; and the reverse primer of Olr1, 50-TGGGGATGG-
TGGAGGCCCTG-30. Coronal sections at the level of the
hippocampus and hypothalamus were hybridized at 55C for
16 hours with the probes. The reacted chromogen on the
sections was colored with alkaline phosphate-labeled anti-
DIG antibody (Roche) and nitroblue tetrazolium/5-bromo-4-
chloro-3-indolyl phosphate.
We performed immunoblotting and ELISA analyses to
evaluate protein expressions of CTL, HIE, HT, and treated
brains. After protein extraction, 20 mg of protein in each
lane was subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis, electroblotted onto a poly-
vinylidene ﬂuoride membrane, and incubated with the
primary antibodies on protein-transferred membranes over-
night at 4C. Proteins were detected with the secondary anti-
rabbit IgG antibody and ECL Prime Western Blotting
Detection Reagent (GE Healthcare, Piscataway, NJ). After
detection of a speciﬁc band, the expression level was
measured by a luminescent image analyzer (ImageQuantlt; B), and HT (48 hours after HI insult; C) group. Each dashed area of the
are signiﬁcantly lower in HIE than in CTL (3 to 72 hours after insult) and is
eans  SD. *P < 0.05, **P < 0.001.
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Akamatsu et alLAS 4000 mini; GE Healthcare) and normalized by
GAPDH expression level. The primary antibodies were
rabbit antibodies against cleaved caspase 3 (cCASP3;
Sigma-Aldrich Co., St. Louis, MO), occludin (Zymed
Laboratories Inc., Carlsbad, CA), ZO-1 (Zymed Labora-
tories Inc.), and GAPDH (Abcam, Cambridge, UK) as a
normalization reference protein. We performed ELISA to
measure malondialdehyde (MDA), by using the Rat MDA
ELISA Kit (CUSABIO, Hubei, China). Samples were
applied on precoated wells with the antibody for MDA.
After the secondary reaction with the biotin-conjugated
antibody, color intensities were measured with a spectrom-
eter. Each sample was measured twice, corrected by the
protein concentration, and calculated to obtain the mean.
The mean was deﬁned as the MDA level.Figure 2 Reduction of apoptosis due to HT. A: HIE cortex shows numerous
rectangular areas. B: In four areas of each cortex (rectangles), the apoptosis ratio
to 0.2 in HT brain. Data are expressed as means  SD. *P < 0.05, **P < 0.001
1846Antibody Treatment Targeting a New Therapeutic
Candidate
As a therapeutic candidate, we selected LOX-1. An antie
LOX-1 neutralizing antibody (R&D Systems, Minneapolis,
MN), 6 mg/kg or 60 mg/kg in PBS, was intraperitoneally
administered immediately after HI insult. We also made the
PBS-treated group, which was injected with 0.1 mL of the
vehicle, PBS. AntieLOX-1 neutralizing antibody or PBS
was injected twice a day until sacriﬁce.
Statistical Analysis
All data were expressed as means  SD. Data among
multiple groups were analyzed with analysis of variance,TUNELþ cells, most of which are NeuNþ. Insets are high-power views of
was calculated. The ratio was 0.4 to 0.6 in HIE brain and was reduced to 0.1
. Scale bar Z 100 mm.
ajp.amjpathol.org - The American Journal of Pathology
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U-test with Statcel 2 (OMS Publication, Saitama, Japan).
P < 0.05 was considered to be statistically signiﬁcant.
Results
Brain Damage of HIE and HT in Neonatal Rats
The sample distribution (Supplemental Table S1) indicated
no signiﬁcant difference between groups in terms of sex and
weight (data not shown). Neonatal HIE models showed
infarction in the lesional (left) hemisphere but not in the
nonlesional (right) hemisphere (Figure 1). The lesional (left)
side pathology, showing infarction and edema, became larger
with time after HI insult, as found in our previous report.15
Changes in infarction size (ratio of intact area) and apoptotic
neuron (apoptosis ratio) in the CTL, HIE, and HT groups 3, 6,
24, 48, or 72 hours after HI insult are shown in Figures 1 and 2.
CTL brains showed no damage to the cerebral hemispheres
throughout the period, whereas HIE brains showed a signiﬁ-
cant reduction in the ratio of intact area, which progressed
rapidly from 3 to 24 hours after HI insult (Figure 1D). In HT
brains, however, the extent of reduction was signiﬁcantly
lower than in HIE brains (Figure 1D).
Next, we compared the number of positive cells under-
going apoptosis in the three groups. No TUNELþ cells were
found in CTL brains (Figure 2). In HIE brains, many
TUNELþ cells were also positive for NeuN (Figure 2A).
Apoptosis ratios at 24, 48, and 72 hours were 0.43  0.08,
0.54  0.05, and 0.49  0.08, respectively. In HT brains,
apoptosis ratios at 24, 48, and 72 hours were 0.10  0.10,The American Journal of Pathology - ajp.amjpathol.org0.23  0.18, and 0.12  0.07, respectively, and were
signiﬁcantly lower than those of HIE (Figure 2B). These
results indicate that HT signiﬁcantly decreased infarct areas
and dramatically reduced the number of apoptotic cells after
HI insult.
Identiﬁcation of Therapeutic Candidate Molecule
from HT
We searched for the molecule most effective for attenuating
HI-induced brain damage by HT. To observe early changes
in gene expression preceding the pathological changes, we
checked microarray data of CTL, HIE, and HT brains 3
hours after HI insult (Supplemental Tables S2 and S3) and
found seven down-regulated genes in neonatal HIE (HIE/
CTL < 0.5); three of them were miRNA (Supplemental
Table S2). Three of the seven genes were overexpressed
during HT after HI insult; gene function was known for one
gene only. We also found 28 genes up-regulated by HI
insult (HIE/CTL > 3) (Supplemental Table S2). Twelve of
them were less expressed in HT brains; 11 of them had
known functions. As a result of qPCR of the 12 genes
(Supplemental Figure S1), the expression level of P2ry13
was signiﬁcantly down-regulated 3 and 6 hours after HI
insult and was up-regulated at 3 and 6 hours after HI insult
with HT. The expression level of Olr1 was signiﬁcantly up-
regulated 3 hours after HI insult and was down-regulated 3
hours after HI insult with HT. Expression levels of the other
genes were not signiﬁcantly different between the groups.
The results of in situ hybridization for P2ry13 and Olr1 are
shown in Supplemental Figure S2. P2ry13þ and Olr1þ cellsFigure 3 Pathological evaluation of antieLOX-1
neutralizing antibody. The brain sections treated
with antieLOX-1 show marked reduction of infarc-
tion area (dashed areas) 48 hours after HI insult,
compared with operated control (A, PBS-T brain; B,
60T brains). C: The ratio of intact area of 60T is
signiﬁcantly higher than in HIE, but that of 6T brains
is not different from those of HIE and PBS-T brains
(48 hours after HI insult).D: The efﬁcacy of 60 mg/kg
antieLOX-1 treatment was noted from 24 hours after
HI insult and was comparable with that of HT. Data
are expressed as means  SD. *P < 0.05,
***P < 0.001.
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campus, thalamus, and hypothalamus. Many of the P2ry13þ
and Olr1þ cells were neurons. Moreover, LOX-1was
expressed in pyramidal neurons of the left lesional cortex
(Supplemental Figure S3).
Effect of AntieLOX-1 Neutralizing Antibody as a
Therapeutic Candidate
From the expression analyses, we suspected that P2ry13was a
neuroprotective factor and Olr1 was a neurodamage-inducing
factor. P2y13 is a purinergic receptor that is expressed in
neurons and exerts an antioxidative effect.22,23 LOX-1 (or
Olr1) is a marker of myocardial infarction and vascular dis-
eases.24e27 We hypothesized that a neutralizing antibody to
LOX-1, an antagonist of LOX-1, may have a therapeutic effect
for neonatal HIE, because LOX-1 is expressed in neurons and
is involved in vascular diseases.27,28
Before using the antibody, we conﬁrmed that it binds to
recombinant rat LOX-1 protein (Sino Biological Inc.,
Beijing, China) by immunoblotting (data not shown).29
We administered 6 mg/kg or 60 mg/kg of antieLOX-1Figure 4 Decreased apoptosis by 60T treatment. A: The 60T brain clearly showe
the PBS-T brain (48 hours after HI insult). Insets are high-power views of rectangul
HIE brains, but that of 6T is not different from those of HIE and PBS-T brains (48 hou
from 24 hours after HI insult and is comparable with that of HT. Data are expresse
1848neutralizing antibody or PBS immediately after HI insult,
twice a day until sacriﬁce after 48 hours. The ratio of the
intact area of 60 mg/kg of antieLOX-1 neutralizing
antibody-treated (60T) brains (Figure 3B) was higher than
that of PBS-treated (PBS-T) brains (Figure 3A). The ratios
of PBS-T brains and 6 mg/kg of antieLOX-1 neutralizing
antibody-treated (6T) brains were not signiﬁcantly different
from that of HIE brains at 48 hours (Figure 3C). The ratio of
60T brains was signiﬁcantly higher than those of HIE and
PBS-T brains (Figure 3C) and was comparable with that of
HT brains. Next, we administered 60 mg/kg of antieLOX-1
neutralizing antibody twice a day until sacriﬁce at 24 or 72
hours and assessed the ratios of intact area sequentially. The
ratio at 24 and 72 hours in the 60T group was 0.51  0.16
and 0.63  0.17, respectively, being signiﬁcantly higher
than those of HIE (0.31  0.12 and 0.31  0.15) and PBS-T
(0.28  0.11 and 0.20  0.07) brains (Figure 3D).
We observed a reduction of HI-induced apoptosis by
antieLOX-1 neutralizing antibody. The number of TUNELþ
cells was large in HIE and PBS-T brains (Figures 2A and 4A)
but was signiﬁcantly smaller in 60T brains (Figure 4A). The
apoptosis ratio at 48 hours was also reduced in 60T brainsd a decrease in the number of TUNELþ cells (mainly neurons), compared with
ar areas. B: The apoptosis ratio of 60T signiﬁcantly decreases, compared with
rs after HI insult). C: The efﬁcacy of 60 mg/kg antieLOX-1 treatment is noted
d as means  SD. *P < 0.05, ***P < 0.001. Scale barZ 100 mm.
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(0.54  0.05), and PBS-T (0.60  0.11) brains (P < 0.001)
(Figure 4B). The apoptosis ratios of 60T brains at 24 and 72
hours were signiﬁcantly reduced (0.09  0.06 and
0.12  0.10, respectively), compared with those of HIE
(0.43  0.08 and 0.49  0.08) and PBS-T (0.33  0.07 and
0.54  0.03) brains (P < 0.001) (Figure 4C).
To examine the antiapoptotic effect of antieLOX-1 anti-
body against neonatal HIE, wemeasured the levels of cCASP3
and MDA. The cCASP3 levels were evaluated due to the
relative expression levels by the immunoblotting, compared
with those of controls. Thus, we could obtain amount of the
unit. No signiﬁcant differences were found in cCASP3 levels
between any groups 24 hours after HI insult (Figure 5A).
However, the cCASP3 levels at 48 and 72 hours were signiﬁ-
cantly lower in 60T brains (0.88  0.33 and 1.29  0.24,
respectively) than in HIE brains (1.99 0.94 and 1.69 0.28)
(P < 0.05). Similarly, the cCASP3 levels at 48 and 72 hours
were signiﬁcantly lower in HT brains (0.96  0.39 and
0.96 0.20) than inHIE brains (P< 0.05).MDA levels of 60T
brains were 61.70  13.5 pmol/protein (mg) at 24 hours,
91.63  59.6 pmol/protein (mg) at 48 hours, and 84.3  49.0
pmol/protein (mg) at 72 hours (Figure 5B).MDA levels ofHIE
brains were 97.97  7.09 pmol/protein (mg) at 24 hours,
169.8 59.7 pmol/protein (mg) at 48 hours, and 220.1 92.3
pmol/protein (mg) at 72 hours. MDA levels of the 60T group
were signiﬁcantly lower than those of theHIEgroup (P< 0.001
at 24 hours, P < 0.05 at 48 and 72 hours) (Figure 5B).
The edema ratio of 60T brains was signiﬁcantly lower than
that of HIE brains at 48 and 72 hours (P< 0.05) (Figure 6A).
Moreover, no signiﬁcant differences were found between HT
and 60T brains at any time. The expression of BBB tight
junction proteins, occludin and ZO-1, was reduced in HIE
brains 48 hours after HI insult (P< 0.05) (Figure 6B) but was
increased in 60T brains (P < 0.001 for occludin, and
P < 0.05 for ZO-1, compared with HIE brains) (Figure 6C).Figure 5 Induction of cCASP3 and MDA expression by antieLOX-1
neutralizing antibody treatment. A: cCASP3 expression is signiﬁcantly
decreased in HT and 60T brains, 48 and 72 hours after HI insult. B: MDA is
similarly decreased in HT and 60T brains at any time point. Data are
expressed as means  SD. *P < 0.05, ***P < 0.001.Discussion
Every year, a large number of babies experience birth
asphyxia, not only in developing countries but also in
developed ones. HT has recently been applied to many babies
who experienced asphyxia. According to the results of recent
clinical trials, it remains difﬁcult for severe cases to survive,
but, in moderate cases, brain damage can be alleviated,7e9,11
showing the neuroprotective effects of HT. The molecular
mechanism includes inhibition of excitatory receptor acti-
vation, activated caspase to induce apoptotic cell death,
mitochondrial failure, free radical damage, lipid peroxida-
tion, and inﬂammation.11 Involvement of speciﬁc biological
pathways has been documented in model animals of neonatal
HIE.11 In this study, we found the role of the LOX-1 pathway
in the pathogenesis and treatment of neonatal HIE.
We veriﬁed that acute temporary HT in a rat model of
neonatal HIE is effective for brain protection.We demonstratedThe American Journal of Pathology - ajp.amjpathol.orga signiﬁcant and reproducible reduction in brain damage 24
hours after HI insult with HT. Moreover, we found that HT
prevented neuronal apoptosis by reducing oxidative stress and
caspase activation and that it ameliorated brain edema by pro-
tecting the BBB tight junction. From the HT experiments, we
discovered a candidate for a novel therapeutic target, LOX-1
(also known as Olr1). The up-regulation of Olr1 was closely
associated with HI-induced brain damage, and its down-
regulation with brain protection by HT. LOX-1 is a receptor
of oxidized LDL, binding to various ligands, such as heat shock
protein 70 and C-reactive protein.24e27 In pathological condi-
tions, LOX-1 is up-regulated by the stimuli of tumor necrosis
factor-a, oxidant species, and reperfusion after ischemia.24e27
The activation of LOX-1 induces apoptosis.24e29 LOX-1 is1849
Figure 6 Improvement of brain edema and the
recoveryof tight junction protein expression by antie
LOX-1 antibody. A: Edema ratios are signiﬁcantly
lower in 60T brains, 48 and 72 hours after HI insult.
Edema ratios of control brains are 1.00. B and C:
Occludin and ZO-1 levels in the lesional side hemi-
sphere are measured in CTL, HIE, HT, and 60T brains
48 hours after HI insult. Each expression level is
standardized by that of GAPDH, and the expression
ratio is compared with the CTL expression ratio.
Data are expressed as means  SD. *P < 0.05,
***P < 0.001.
Akamatsu et alexpressed in endothelial cells and vascular smooth muscle
cells. Its pathogenetic role in atherosclerosis has been estab-
lished.24,25,27,30 As we showed here by in situ hybridization,
LOX-1 is expressed in neurons. LOX-1 induces neuronal
apoptosis in hypertensive rats.31 An antieLOX-1 neutralizing
antibody reduces LOX-1 concentration and activation. In an
atherosclerosis model mouse, this antibody has been success-
fully applied to improve vascular function in adult animals.29,32
In our model, the same antibodywas also effective for neonatal
HIE, and its efﬁcacy was comparable with that of HT. The
antibody inhibited both brain edema and neuronal apoptosis.
Our data show that one of themechanisms of its efﬁcacy isBBB
protection. Damage of vascular endothelial cells leads to brain
edema through incomplete BBB of the neonates’ brain. After
HI insult, LOX-1 up-regulation induces matrix metallo-
proteinase expression, which in turn degrades tight junction
proteins.26,33e35 Occludin and ZO-1 are tight junction proteins
and major components of BBB, clinically used as markers of
BBB breakdown.36 In this study, ZO-1 expression was up-
regulated by both HT and antieLOX-1 neutralizing antibody.
By contrast, occludin expression was up-regulated by anti-
eLOX-1 neutralizing antibody but not by HT. The LOX-1
signaling pathway may specially regulate occludin expression
to maintain BBB. This protection of BBB and the following
suppression of brain edema may lead to the inhibition of
neuronal apoptosis.
Some neuronal damage in neonatal HIE is caused by the
induction of apoptotic cell death through oxidative stress
and active caspase. LOX-1 activation increases the amount1850of cleaved caspase 3, an active form of caspase 3 and a
strong apoptosis-inducing protein.37 MDA is a product of
lipid peroxidation from oxidative stress. It directly dam-
ages DNA and induces apoptotic cell death. The damage
of vascular endothelial cells leads to BBB breakdown, and
the neuronal damage leads directly to brain damage. Our
results suggest that the antibody-induced reduction of
LOX-1 concentration and activation may inhibit damage
of vascular endothelial cells and neurons at the early stage
of neonatal HIE.
We noted that HI insult and HT altered the expression of 12
genes, encoding cytokines, chemokines, noncoding RNA,
transcription factors, and receptors. Among them, we found
signiﬁcant changes in the expression of P2ry13 and Olr1 by
qPCR and in situ hybridization. P2ry13 encodes P2y13, a
receptor of ADP that is expressed in the neuron. It
has been reported that the selective agonist of P2y13,
2-methylthioladenosine 50 diphosphate (2MeSADP), sup-
presses oxidative stress-induced neuronal death and that
2MeSADP recovered cytotoxic edema and brain infarcts.22,23
We attempted administration of 2MeSADP in our rats with
neonatal HIE, by injecting 0.25, 2.5, or 25 mg/kg 2MeSADP
once a day from just after HI insult. However, pathological
studies showed no evidence of its efﬁcacy (data not shown).
Previous studies have shown that active P2y13 inhibits
neuronal differentiation and even induces apoptosis.38,39 Taken
together, it may be difﬁcult to use P2y13 as a therapeutic target.
Our neonatal HIE rat has been modiﬁed and widely used
as a standard of neonatal HIE model.2,18 The rat brain atajp.amjpathol.org - The American Journal of Pathology
LOX-1 Is Neonatal HIE Therapeutic Targetpostnatal day 7 is known to be histologically similar to that
of a term human fetus or newborn infant, showing complete
cerebral cortical neuronal layering, involute germinal ma-
trix, and little myelination of white matter.40 Thus, the rat
brain at postnatal day 7 is reasonable as the HIE model. Of
course, one must challenge other models to provide ﬁrm
treatment with antieLOX-1 antibody.
Conclusion
Our study identiﬁed LOX-1 as a novel therapeutic target for
neonatal HIE. Although many problems need to be
addressed before its clinical application, the inhibition of
LOX-1 may become a novel treatment for babies who
experienced asphyxia in the near future.Acknowledgments
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